Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of GONAL-f + Luveris ovarian stimulation starting Day 1 vs Day 6 in ART for women aged 36–42
IRCT201202128977N1Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of follitropin alfa and lutropin alfa in infertility (2 arms), sponsored by Merck & Co. Primary endpoints: Efficacy of ovarian stimulation regimen (Day 1 vs Day 6 start) and Safety of ovarian stimulation regimen (Day 1 vs Day 6 start). Started Feb 2012; status: completed.
02
Drugs
follitropin alfalutropin alfa
03
Conditions
infertility
Beyond the preview
Go deeper on IRCT201202128977N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201202128977N1.